Brief: Cingulate Initiates Phase 3 Study Of Lead Asset Ctx-1301, Designed As A True Entire Active-Day Treatment For ADHD

Cingulate

04/01/2023 11:46

Jan 4 (Reuters) - Cingulate Inc  CING.O :
    * CINGULATE INITIATES PHASE 3 STUDY OF LEAD ASSET CTX-1301,
DESIGNED AS A TRUE ENTIRE ACTIVE-DAY TREATMENT FOR ADHD
    * CINGULATE INC - TRIAL RESULTS EXPECTED 1H 2023
    * CINGULATE INC - PHASE 3 CLINICAL TRIAL PROGRAM FOR
CTX-1301 WILL
BE CONDUCTED IN U.S. & INSTRUMENTAL FOR FILING OF NDA TO FDA,
EXPECTED IN H1 OF 2024

Source text for Eikon:  urn:newsml:reuters.com:*:nGNXbLXWlz
Further company coverage:  CING.O 
 ((Reuters.Briefs@thomsonreuters.com;))